Development and clinical trials of the new human rabies vaccine of tissue culture (human diploid cell) origin

Abstract

A new type of rabies vaccine for human prophylaxis was developed by workers at the Wistar Institute, Philadelphia, Pa. Vaccine is prepared from rabies virus infected tissue cultures of human diploid cells and is inactivated following concentration and purification of virus. Vaccine is being successfully used for prophylactic and postexposure treatment in humans with reduced number of doses and is virtually free from adverse reactions associated with the use of other types of rabies vaccines.